演題詳細

ポスター / Poster

ポスター 9 (Poster 9) :CML:臨床1 (CML:Clinical Research 1)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
田中 英夫 (Hideo Tanaka):1
1:広島市立安佐市民病院 血液内科
 
前へ戻る

Muscle cramps as the low-grade adverse events of imatinib improved with changes to nilotinib

演題番号 : PS-1-64

加藤 裕一 (Yuichi Kato):1、塩野 洋介 (Yosuke Shiono):1、鈴木 郁子 (Ikuko Suzuki):1、高野 桂 (Kei Kohno):1、加藤 丈夫 (Takeo Kato):1

1:Department of Hematology, Yamagata University, Japan

 

The majority of chronic myeloid leukemia patients treated with imatinib(IM) experience low-grade adverse events (AEs) that either resolve or diminish over time. Nevertheless, AEs can negatively impact a patient's adherence to therapy. Nonadherence to IM therapy is correlated to lack of optimal treatment responses and has been identified as an important factor. Muscle cramp, that is a factor that detracts from the quality of life, is high frequent AE in patients treated with IM. For 6 patients switch from IM to nilotinib (NIL), we analyzed retrospectively for state of muscle spasm, creatine phosphokinase (CK) and treatment response after switch from IM to NIL. Muscle cramps and increase of CK were confirmed in all 6 patients after administration of IM. Therapeutic responses of IM in these patients were partial cytogenetic response or less than 5 copies of Amp-CML. After switch from IM to NIL, muscle cramps disappeared in all patients within 6 weeks. CK has recovered to the normal range in all patients (p = 0.005, t-test). Treatment response in 5 patients reached less than 5 copies of Amp-CML after switch to NIL. There were reports in ENRICH study (ASH2012), low-grade AEs improved by switching from IM to NIL, and quality of life has improved. Our analysis was similar to the result of this study. The majority of nonhematologic IM-related low-grade AEs as muscle cramp improved within 6 weeks after switching to NIL.

前へ戻る